SG11202007241WA - Nucleic acid antibody constructs for use against respiratory syncytial virus - Google Patents

Nucleic acid antibody constructs for use against respiratory syncytial virus

Info

Publication number
SG11202007241WA
SG11202007241WA SG11202007241WA SG11202007241WA SG11202007241WA SG 11202007241W A SG11202007241W A SG 11202007241WA SG 11202007241W A SG11202007241W A SG 11202007241WA SG 11202007241W A SG11202007241W A SG 11202007241WA SG 11202007241W A SG11202007241W A SG 11202007241WA
Authority
SG
Singapore
Prior art keywords
nucleic acid
respiratory syncytial
syncytial virus
antibody constructs
use against
Prior art date
Application number
SG11202007241WA
Other languages
English (en)
Inventor
David Weiner
Kar Muthumani
Jing Chen
Trevor Smith
Katherine Schultheis
Original Assignee
Wistar Inst
Inovio Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wistar Inst, Inovio Pharmaceuticals Inc filed Critical Wistar Inst
Publication of SG11202007241WA publication Critical patent/SG11202007241WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG11202007241WA 2018-01-31 2019-01-31 Nucleic acid antibody constructs for use against respiratory syncytial virus SG11202007241WA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862624320P 2018-01-31 2018-01-31
US201862749580P 2018-10-23 2018-10-23
PCT/US2019/015975 WO2019152600A1 (en) 2018-01-31 2019-01-31 Nucleic acid antibody constructs for use against respiratory syncytial virus

Publications (1)

Publication Number Publication Date
SG11202007241WA true SG11202007241WA (en) 2020-08-28

Family

ID=67478343

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202007241WA SG11202007241WA (en) 2018-01-31 2019-01-31 Nucleic acid antibody constructs for use against respiratory syncytial virus

Country Status (11)

Country Link
US (1) US20210047390A1 (zh)
EP (1) EP3746474A4 (zh)
JP (1) JP2021512600A (zh)
KR (1) KR20200140799A (zh)
CN (1) CN111936513A (zh)
AU (1) AU2019215006A1 (zh)
BR (1) BR112020015588A2 (zh)
CA (1) CA3089717A1 (zh)
MX (1) MX2020008062A (zh)
SG (1) SG11202007241WA (zh)
WO (1) WO2019152600A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110167584B (zh) * 2016-11-07 2024-06-07 威斯塔解剖学和生物学研究所 用于针对莱姆病的dna抗体构建体

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7240096A (en) * 1995-09-18 1997-04-09 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Neutralizing monoclonal antibodies to respiratory syncytial virus
CA2468246A1 (en) * 2001-11-26 2003-06-05 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Increasing electro-gene transfer of nucleic acid molecules into host tissue
GB0306618D0 (en) * 2003-03-22 2003-04-30 Univ Newcastle Antibody
PT2477603E (pt) * 2009-09-17 2016-06-16 Baxalta Inc Co-formulação estável de hialuronidase e imunoglobulina e métodos para a sua utilização
US8568726B2 (en) * 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
KR101896124B1 (ko) * 2010-07-09 2018-09-07 얀센 백신스 앤드 프리벤션 비.브이. 항-인간 호흡기 세포융합 바이러스(ｒｓｖ) 항체 및 사용 방법
WO2015089492A2 (en) * 2013-12-13 2015-06-18 The Trustees Of The University Of Pennsylvania Dna antibody constructs and method of using same
TWI659968B (zh) * 2013-03-14 2019-05-21 再生元醫藥公司 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法
EP4353316A2 (en) * 2014-01-15 2024-04-17 Medimmune Limited Rsv-specific antibodies and functional parts thereof
EP3297670A4 (en) * 2015-05-20 2019-03-06 Immunwork Inc. MOLECULAR CONSTRUCTIONS WITH TARGETING ELEMENTS AND EFFECTORS AND THEIR APPLICATIONS
JO3555B1 (ar) * 2015-10-29 2020-07-05 Merck Sharp & Dohme جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
SG10202011016WA (en) * 2016-05-05 2020-12-30 Univ Pennsylvania Dna antibody constructs for use against pseudomonas aeruginosa

Also Published As

Publication number Publication date
US20210047390A1 (en) 2021-02-18
WO2019152600A1 (en) 2019-08-08
CN111936513A (zh) 2020-11-13
EP3746474A4 (en) 2021-12-15
EP3746474A1 (en) 2020-12-09
BR112020015588A2 (pt) 2021-01-05
KR20200140799A (ko) 2020-12-16
MX2020008062A (es) 2020-12-03
JP2021512600A (ja) 2021-05-20
AU2019215006A1 (en) 2020-09-17
CA3089717A1 (en) 2019-08-08

Similar Documents

Publication Publication Date Title
HK1254950A1 (zh) 中和人體呼吸道合胞體病毒的抗體
EP3551193A4 (en) NUCLEIC ACID VACCINES AGAINST RESPIRATORY VIRUSES
EP3595713A4 (en) RESPIRATORY SYNCYTIAL VIRUS VACCINE
IL258831A (en) Assemble respiratory syncytial virus
EP3385278A4 (en) Full human antibody against respiratory syncytial virus
EP3585429A4 (en) ANTI-IL31 ANTIBODIES FOR USE IN VETERINARY MEDICINE
ZA201800938B (en) Monoclonal antibodies specifically for phosphoprotein of the human respiratory syncytial virus and the methods of use
IL277472A (en) Nucleic acid molecules for pseudouridylation
IL278061A (en) Structures of antibodies against ROR
EP3621640A4 (en) OPTIMIZED NUCLEIC ACID ANTIBODIES CONSTRUCTIONS
LT2950886T (lt) Respiracinio sincitinio viruso f baltymo epitopai
HK1246781A1 (zh) 呼吸道合胞病毒抑制劑
DK3265121T3 (da) Markørsystem, især for baculovirus-eksprimerede underenhedsantigener
IL275910A (en) Methods for viral nucleic acid analysis
IL275296A (en) Epstein-Barr virus antigen structures
ZA201800940B (en) Use of il-3, il-33, and il-12p40 for characterization of the respiratory infections by syncytial respiratory virus
EP3601334A4 (en) DNA ANTIBODY CONSTRUCTS FOR USE AGAINST HIV
SG11202007241WA (en) Nucleic acid antibody constructs for use against respiratory syncytial virus
EP3212666A4 (en) Human monoclonal antibody specific for the f protein of respiratory syncytial virus (rsv)
SG10202011017RA (en) Filovirus consensus antigens, nucleic acid constructs and vacciens made therefrom, and methods of using same
EP3277707A4 (en) Antibodies against infectious diseases
SG10202011021XA (en) Dna monoclonal antibodies targeting influenza virus
SG11201704201VA (en) Catalyst and preparation method thereof, and method for preparing isobutylene by applying the same
EP3548054A4 (en) ANTI-DNA ANTIBODY CONSTRUCTIONS FOR USE AGAINST EBOLA VIRUS
EP3383428A4 (en) VACCINE AGAINST SYNCYTIAL RESPIRATORY VIRUS